Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Carboplatin for DNA Repair Deficient mCRPC
NCT02985021Phase 2Terminated
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
- Start
- Nov 2016
- Primary completion
- Apr 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Seattle Institute for Biomedical and Clinical Research. Primary endpoint: Percentage of Patients Achieving >= 50% Reduction in PSA. Started Nov 2016; status: terminated.
02
Drugs
carboplatin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02985021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985021.